Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
01 1Biophore India Pharmaceuticals Private Limited
02 1Aurobindo Pharma Limited
01 2Erythromycin Lactobionate
01 2India
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-006
Start Marketing Date : 2020-02-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-403
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
A Erythromycin Lactobionate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromycin Lactobionate, including repackagers and relabelers. The FDA regulates Erythromycin Lactobionate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromycin Lactobionate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Erythromycin Lactobionate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Erythromycin Lactobionate supplier is an individual or a company that provides Erythromycin Lactobionate active pharmaceutical ingredient (API) or Erythromycin Lactobionate finished formulations upon request. The Erythromycin Lactobionate suppliers may include Erythromycin Lactobionate API manufacturers, exporters, distributors and traders.
click here to find a list of Erythromycin Lactobionate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Erythromycin Lactobionate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Erythromycin Lactobionate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Erythromycin Lactobionate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Erythromycin Lactobionate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Erythromycin Lactobionate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Erythromycin Lactobionate suppliers with NDC on PharmaCompass.
We have 2 companies offering Erythromycin Lactobionate
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
